Compounds of the formula I
wherein either R₁ is halogen, R₁′ is halogen or hydrogen and R₂ and R₂′ denote hydrogen or R₁ and R₁′ represent hydrogen, R₂ is an aliphatic or aromatic radical and R₂′ is hydroxy or R₂ and R₂′ together represent oxo, and wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms or, if R₁ and R₁′ denote hydrogen, R₂ represents an aromatic radical and R₂′ is hydroxy, R represents methyl, and their salts are useful as nootropics, antidepressants and/or anxiolytics. The can be manufacture by replacing any group R₅ by hydrogen and/or converting any group Z₀ into amino in a compound of formula II
in which R, R₁, R₁′, R₂ and R₂′ have their previous significances, Z represents a protected or latent amino group Z₀ and R₄ denotes hydrogen or a hydroxy-protective group R₅, and wherein amino as a constituent of R and/or hydroxy R₂′ or oxo R₂ + R₂′ may be present in a temporarily protected form.
Phosphinic Acid Analogs of GABA. 1. New Potent and Selective GABAB Agonists
作者:Wolfgang Froestl、Stuart J. Mickel、Roger G. Hall、Georg von Sprecher、Dietrich Strub、Peter A. Baumann、Felix Brugger、Conrad Gentsch、Joachim Jaekel
DOI:10.1021/jm00017a015
日期:1995.8
replacing the carboxylic acid group of GABA or baclofen derivatives with either the phosphinic acid or the methylphosphinic acid residue. Surprisingly, ethyl- and higher alkylphosphinic acid derivatives of GABA yielded novel GABAB antagonists, which are described in part 2 of this series. Structure-activity relationships of the novel GABAB agonists are discussed with respect to their affinities to GABAB